50 Big Debates in Gynecologic Oncology

Dennis S. Chi is the Ronald O. Perelman Chair in Gynecologic Surgery, Deputy Chief of the Gynecology Service, and Head of Ovarian Cancer Surgery at Memorial Sloan Kettering Cancer Center, New York, NY. Nisha Lakhi is the Senior Director of Clinical Oncology and Director of Research at Richmond University Medical Center, Staten Island, NY. She lead her institution's Cancer Program with special emphasis on gynecologic oncology and cancer survivorship and recently received the national “40 under 40 Cancer Award (2019)”. Nicoletta Colombo is Professor of Gynecological Oncology, University of Milan-Bicocca. She was President of ESGO from 2011-2013, chair of the ESMO-ESGO-ESP consensus Conference on endometrial Cancer in 2016 and Chair of ESMO-ESGO Ovarian Cancer Consensus Conference in 2019. She is chair elect of ENGOT (2022-2024).

Section I: Perioperative Management; 1A. Should routine mechanical bowel preparation be performed before primary debulking surgery? Yes Lea A. Moukarzel and Oliver Zivanovic; 1B. Should routine mechanical bowel preparation be performed before primary debulking surgery? No Shannon Armbruster and Fidel A. Valea; 2A . Should preoperative carbohydrate loading be routine prior to debulking surgery? Yes Arwa Mohammad, Deepa Maheswari M. Narasimhulu and Sean C. Dowdy; 2B. Should preoperative carbohydrate loading be routine prior to debulking surgery? No Kathryn Miller, Dib Sassine and Yukio Sonoda; Section II: Screening, Prevention and Early Diagnosis; 3A. Should women with BRCA mutations be offered bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction? Yes Thomas Boerner and Kara Long Roche; 3B. Should women with BRCA mutations be offered bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction? No Steven A. Narod; 4A. Can high-risk HPV testing be used alone as the primary screening modality for cervical cancer? Yes Thomas C. Wright; 4B. Can high-risk HPV testing be used alone as the primary screening modality for cervical cancer? No Ibraheem O. Awowole and Olusegun O. Badejoko; Section III: Ovarian Cancer; 5A. Should CA-125 surveillance be performed after completion of primary treatment for ovarian cancer patients in remission? Yes Eseohi Ehimiaghe and Edward Tanner; 5B. Should CA-125 surveillance be performed after completion of primary treatment for ovarian cancer patients in remission? No Gordon J. S. Rustin; 6A. In patients with BRCA-negative and HRD-negative epithelial ovarian cancer, should molecular profiling be routinely done to guide adjuvant therapy? Yes Ilaria Betella and Matteo Repetto; 6B. In patients with BRCA-negative and HRD-negative epithelial ovarian cancer, should molecular profiling be routinely done to guide adjuvant therapy? No Raanan Alter and Ernst Lengyel; 7A. Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse? Yes Rachel N. Grisham; 7B. Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse? No David M. Gershenson; 8A. Should Stage IC mucinous ovarian carcinoma be managed by observation or adjuvant chemotherapy? Observation Jason D. Wright; 8B. Should Stage IC mucinous ovarian carcinoma be managed by observation or adjuvant chemotherapy? Adjuvant chemotherapy Jonathan Ledermann and Sophia Wong; 9A. How many cycles of adjuvant chemotherapy should be administered to patients with high-risk Stage I epithelial ovarian cancer? Three cycles Annalisa Garbi, Eleonora Zaccarelli and Federica Tomao; 9B. How many cycles of adjuvant chemotherapy should be administered to patients with high-risk Stage I epithelial ovarian cancer? Six cycles John K. Chan and Daniel S. Kapp; 10A. Patients with advanced ovarian cancer who are 75 years old and older should routinely be treated withneoadjuvant chemotherapy: Yes Michelle Davis and Ursula Matulonis; 10B. Patients with advanced ovarian cancer who are 75 years old and older should routinely be treated with neoadjuvant chemotherapy: No Olga T. Filippova and William P. Tew; 11A. Should an attempt at aggressive cytoreduction be made for all surgical candidates with advanced ovarian cancer prior to treatment with adjuvant chemotherapy? Yes Sven Mahner, Anca Chelariu-Raicu and Fabian Trillsch; 11B. Should an attempt at aggressive cytoreduction be made for all surgical candidates with advanced ovarian cancer prior to treatment with adjuvant chemotherapy? No Sean Kehoe and Jason Yap; 12A. Should minimally invasive modalities be routinely/uniformly utilized for assessment of resectability prior to attempted primary debulking in patients with advanced ovarian cancer? Yes Juliet E. Wolford